用左心室辅助器件进行抗血栓策略
Maja Cikes1, Melana Yuzefpolskaya2, Finn Gustafsson3
1Department of Cardiovascular Diseases, University of Zagreb School of Medicine, University Hospital Center Zagreb, Zagreb, Croatia.
Journal of cardiac failure
|August 18, 2024
概括
左心室辅助器件 (LVAD) 的进步改善了患者的治疗结果. 新的抗凝血策略可以控制血栓和出血等风险,但持续的研究对于最佳的心力衰竭治疗至关重要.
科学领域:
- 心脏病学 心脏病学
- 生物医学工程 生物医学工程
- 药理学 药理学是指药理学的学科.
背景情况:
- 左心室辅助器件 (LVAD) 改善了晚期心力衰竭的长期结果.
- 改进的工程提高了LVAD的耐用性和血液相容性.
- 血栓,中风和出血等不良事件是特定于设备的.
研究的目的:
- 审查目前对LVAD患者的抗凝血管理策略.
- 突出技术的进步及其对不良事件的影响.
- 讨论对LVAD治疗的进一步研究的必要性.
主要方法:
- 关于LVADs和抗凝固剂的当前文献的综述.
- 分析特定于设备的不良事件概况.
- 对修改后的抗血栓策略的评估.
主要成果:
- 全磁悬浮转子LVAD可以减少血栓形成和中风风险.
- 修改后的抗凝剂 (降低剂量的VKA,DOAC) 显示安全性,并减少粘膜层出血.
- 消除抗血小板剂有助于减少出血事件.
结论:
- 在LVAD患者的抗凝固管理正在随着新疗法而发展.
- 需要仔细应用新兴技术和疗法.
- 持续的研究对于优化LVAD患者护理和结果至关重要.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405
Anticoagulant Drugs: Low-Molecular-Weight Heparins
654
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
654
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K


